Biodesign’s investment framework is referred to as a translation or innovation engine.
Our research portfolio ranges from early stage fundamental or exploratory research, where the eventual application is uncertain, to mature projects that are on the threshold of translation to clinical trials, development by industrial partners or launch as Biodesign spin-out companies. Biodesign's investment framework focuses on the development and commercialization of Biodesign’s research, and management of the investment in technology translation. It also provides a mechanism for collaborations that result in commercial products, clinical practices and agency program outcomes.
The lack of available funding has caused promising technologies to languish, because there are often insufficient resources to address the critical needs and barriers to the translation and commercialization of a technology.
The Biodesign Institute has developed several vehicles to cross this “valley of death” by adding value to companies to overcome the funding gap between discovery and delivery. Biodesign, in conjunction with Skysong Innovations (SI), is taking a proactive approach to discovering the match between Biodesign’s research output and important commercial products and services. Our strategy engages a large number of external experts familiar with solving important problems through commercialization. It also engages Biodesign’s researchers with these experts to discover which technology platforms have promise as commercial products. The goal is to drive rapid performance improvement, resulting in more commercial product options for each of Biodesign’s research outcomes. The objective is to significantly increase the number of invention disclosures and commercialization outcomes from Biodesign’s research.
SI's technology licensing process is designed to achieve two goals:
- Offering a straightforward legal mechanism for companies to access ASU inventions.
- Facilitating on-going partnerships for future product commercialization.
SI shares in the development risk by requiring an initial license fee and a royalty that is received only after a product or process is being sold or otherwise used.
Please review SI's technology portfolio to view our available inventions. When you find one you are interested in, please let us know. If you do not find what you are looking for, please feel free to call us to see if there are any pending technologies in your field of interest.
Arizona Bioscience Community
A broad coalition of elected, civic and community leaders have recognized the importance of attracting leading-edge research to Arizona as an engine for new economic development and the development and retention of a highly skilled workforce. Biodesign actively supports these efforts through its involvement with regional economic development organizations including:
- Arizona BioIndustry Association (AZBio). Biodesign is a participating member of this trade association which promotes the development of a robust bioscience industry in Arizona. Our Executive Director serves on AZBio’s board of directors, and Biodesign has been a major supporter of AZBio events.
- Greater Phoenix Economic Council (GPEC). Biodesign provides active support to this regional economic development organization on many fronts. Biodesign mentored managers from GPEC on the regional research capabilities and bioscience industry issues. Biodesign has also actively participated in GPEC’s efforts to recruit new companies to Arizona by conducting tours and research review meetings at the Institute. Successfully recruited bioscience companies include: Covance, InNexus, Abraxis and Insys.
- Arizona Bioscience Roadmap. Biodesign is an active participant in this strategic planning and coordination effort sponsored by the Flinn Foundation in collaboration with the Battelle Institute. Biodesign administrators and researchers serve on the steering committee and several of the research sub-committees to advance bioscience areas of strategic interest to Arizona.